• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Theralase Photodynamic Compounds Destroy Cancer
 

Theralase Photodynamic Compounds Destroy Cancer

on

  • 238 views

Theralase Technologies Inc. (TSX-V: TLT) announced today the successful results of preclinical studies (in-vitro and in-vivo) demonstrating significant destruction of various brain and colon cancer ...

Theralase Technologies Inc. (TSX-V: TLT) announced today the successful results of preclinical studies (in-vitro and in-vivo) demonstrating significant destruction of various brain and colon cancer cell lines. The new proprietary Theralase treatment sharply delayed the tumour progression, when attacked by the Theralase patented light activated Photo Dynamic Compounds (PDCs), signifying a new and broadly promising approach to cancer treatment. When treated with the Theralase PDCs, cancerous mice survived cancer-free for more than 100 days post-treatment, a highly significant milestone.

Statistics

Views

Total Views
238
Views on SlideShare
238
Embed Views
0

Actions

Likes
0
Downloads
2
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Theralase Photodynamic Compounds Destroy Cancer Theralase Photodynamic Compounds Destroy Cancer Document Transcript

    • Press Release Theralase Photo Dynamic Compounds Destroy CancerToronto, Ontario – October 22, 2012, Theralase Technologies Inc. (TSX-V: TLT) announced today thesuccessful results of preclinical studies (in-vitro and in-vivo) demonstrating significant destruction ofvarious brain and colon cancer cell lines. The new proprietary Theralase treatment sharply delayed thetumour progression, when attacked by the Theralase patented light activated Photo DynamicCompounds (PDCs), signifying a new and broadly promising approach to cancer treatment. Whentreated with the Theralase PDCs, cancerous mice survived cancer-free for more than 100 days post-treatment, a highly significant milestone.The scientific data supporting this breakthrough was presented and well received recently at the 9thInternational Symposium of Photodynamic Therapy and Photodiagnosis in Clinical Practice held inBrixen, Italy. The Theralase presentation was made by Dr. Lothar Lilge, Senior Scientist, Ontario CancerInstitute / Princess Margaret Cancer Centre, University Health Network (UHN) and confirms thesignificance of the successful research conducted by Theralase in collaboration with UHN scientists,validating this scientific work on the international stage.Dr. Lothar Lilge stated that, "These preclinical results demonstrate that the Theralase Photo DynamicCompounds appear to be highly effective (100% cancer cell kill) when used to destroy various cancercell lines in-vitro; specifically, brain glioma (U-87 and F-98) and in-vivo; specifically, colon cancer (CT-26WT), in the treatment of subcutaneous cancer tumours in Balb/c mice. Mice enrolled in the study,presented with subcutaneous cancerous lesions of approximately 6 mm in size prior to treatment,which is standard for these preclinical models. The statistically significant improvement in survivaltimes make these results even more encouraging, as a number of mice are still alive today living cancerfree, 100 days post treatment. Moreover, we believe that tested PDCs may have potential for Type I(oxygen independent) PDT effect; hence, their clinical use would represent a significant gain in cancertherapy.”Dr. Arkady Mandel, Chief Scientific Officer at Theralase Inc. stated that, "We were delighted with theextremely promising results of our latest cancer studies, which demonstrate significant anticancerdestruction of Theralase’s PDCs in all tested in-vitro studies and in difficult to treat in-vivo cancermodels, without significant optimization. With optimization, the ability of the Theralase PDCs to targetand destroy cancerous tumours could be even more enhanced. There are a number of obviousadvantages for the use of Theralase’s PDCs in the destruction of cancer that have been established bythis body of work, such as: the Photo Dynamic Therapy (PDT) effect has been achieved at lowerconcentrations compared to aminolevulinic acid, also known as ALA (ALA is a currently approved FDAPDC) and with lower dark toxicity (PDC alone with no light) compared to methylene blue (anotherPDC), the Theralase PDCs have potential for Type I (oxygen independent) PDT effect and lastly wereable to induce tumour necrosis (cell death) in mice that allowed prolonged survival, cancer free, inexcess of 100 days of observation. New evidence from experimental and clinical studies increasinglypoints to a lack of oxygen content or hypoxia in solid tumours to be strongly associated with tumourpropagation, malignant progression and resistance to therapy and it has thus become one of thecentral issues in tumour physiology and cancer treatment. Therefore, with the latest scientific data in
    • Press Releasehand, Theralase’s PDT has the potential to become more expeditiously integrated into the mainstreamof cancer treatment.”Roger Dumoulin-White, President and CEO of Theralase stated, “This new research extends theopportunity of Theralase’s patented PDC technology to have a successful impact on two additionaldevastating forms of cancer; specifically, brain and colon cancer. Our research has demonstrated a killrate of effectively 100% in specific human brain and colon cancer cells lines. With the high mousesurvival rate, which is approximately equivalent to 11 years “cancer free” in humans, being observed inthis study, these results lay the groundwork for further preclinical work for these specific cancers. If thepreclinical work is proven successful, this would lead to human clinical trials as early as 2013. Theralaseplans to aggressively pursue commercialization of its ground-breaking PDT technology through the FDAregulatory approval process and is on track to commence FDA Phase 1 human clinical trials as early asthis time next year. Theralase plans to continue its research and development at an accelerated paceto optimize and expand its growing patent portfolio of PDCs that are able to destroy a variety of lifethreatening cancers.”About Theralase Technologies Inc.:Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralasetechnology is safe and effective in treating pain, inflammation and for tissue regeneration of neuralmuscular skeletal conditions and wound healing. Theralase is currently developing patented PhotoDynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses whenlight activated by Theralase’s proprietary and patented laser technology.For further information please visit www.theralase.com , regulatory filings may be viewed by visitingwww.sedar.com.This press release contains forward-looking statements, which reflect the Companys current expectations regarding future events. The forward-lookingstatements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation toupdate these forward-looking statements.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) acceptsresponsibility for the adequacy or accuracy of this release.For More InformationRoger Dumoulin-WhitePresident & CEO,416-447-8455 ext. 225rwhite@theralase.comKristina HacheyChief Financial Officer416-447-8455 ext. 224khachey@theralase.comArkady Mandel
    • Press ReleaseChief Scientific Officer416-447-8455 ext. 242amandel@theralase.comGreg BewshDirector of Investor Relations,416-447-8455 ext. 262gbewsh@theralase.com